Caspofungin Market - Snapshot

Caspofungin is an antifungal drug that works by inhibiting the enzyme (1→3)-β-D-glucan synthase, thereby disturbing the integrity of the fungal cell wall. Caspofungin acetate was first approved by the U.S. Food and Drug Administration (FDA) on January 26, 2001, then by the European Medicine Agency (EMA) on October 24, 2001, and approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on January 18, 2012. It was developed and marketed as Cancidas by Merck Sharp & Dohme (U.S.).

The global caspofungin market was valued at US$ 484.60 Mn in 2018 and is anticipated to reach US$ 496.20 Mn by 2027, expanding at a CAGR of 0.18% from 2019 to 2027. Rise in prevalence of candidiasis, increase in usage of echinocandins, surge in disposable income in the emerging countries, and rise in awareness among people about preventive measures of various microbial diseases are factors projected to propel the global market during the forecast period.

caspofungin market

The incidence and prevalence of invasive candidiasis are rising significantly across the world, affecting millions of people. Increase in incidence of candidaemia in ICUs has been reported in several parts of the world. According to the Extended Prevalence in Intensive Care (EPIC) II point prevalence study, Candida spp. is the third most recurrent cause of infection in ICUs across the globe, accounting for 17% of all ICU infections in culture-positive infected patients. Moreover, according to the U.S. Department of Health & Human Services, invasive candidiasis is one of the common health care-associated infections. Around 46,000 cases of invasive candidiasis occur each year in the U.S. Candida species are ranked fifth among hospital-acquired pathogens and fourth among nosocomial blood stream infection pathogens. Increase in incidence of invasive candidiasis is expected to be a major factor likely to boost the global caspofungin market during the forecast period.

The global caspofungin market has been segmented based on indication, distribution channel, and region. In terms of indication, the candidiasis segment is projected to account for major share of the global market during the forecast period. Caspofungin has been approved as first line of treatment of patients suffering from invasive candidiasis and who are resistant to other antifungal agents. It has been also approved as first line of treatment for different forms of candidiasis such as esophageal candidiasis, intra-abdominal abscesses, peritonitis, and pleural space infections. The preferred use of caspofungin over other antifungals in certain diseases is likely to propel the market during the forecast period.

In terms of region, the global caspofungin market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Developed regions such as North America and Europe accounted for leading shares of the global market in 2018. Large patient population and presence of major pharmaceutical companies can be attributed to high share of these regions. Moreover, rise in prevalence of fungal diseases and increase in the geriatric population drive the caspofungin market in North America and Europe. The market in Asia Pacific is projected to expand at a high CAGR owing to rapidly improving health care facilities in countries such as India, China, South Korea, and Malaysia. China dominated the caspofungin market in Asia Pacific in 2018. The market in India is anticipated to expand at a significant CAGR during the forecast period. Furthermore, increase in investment by leading players and introduction of generics by other players are expected to fuel the growth of the market in the region. The market in Latin America and Middle East & Africa is likely to expand at a steady pace during the forecast period.

Prominent players operating in the global caspofungin market include Teva Pharmaceutical Industries Ltd., Mylan N.V , Merck & Co., Inc., Fresenius SE & Co. KGaA , Gland Pharma Limited, and Xellia Pharmaceuticals.

Caspofungin Market - Snapshot

Caspofungin is a lipopeptide antifungal drug from Merck & Co., Inc. discovered by James Balkovec, Regina Black and Frances A. Bouffard. It is a member of a new class of antifungals termed the echinocandins. It works by inhibiting the enzyme glucan synthase and thereby disturbing the integrity of the fungal cell wall. Caspofungin was the first inhibitor of fungal glucan synthesis to be approved by the United States Food and Drug Administration.

Caspofungin is administered intravenously. It has been effective in treating fungal infections caused by Aspergillus and Candida species. It is a member of the echinocandin family, a new class of antifungal agents with broad spectrum of activity against all Candida species. In comparison to treatment with either fluconazole or Amphotericin B, all three drugs in this class have been demonstrated to be highly effective or superior in well-defined clinical settings including invasive Candida infections, Candida oesophagitis and candidaemia. Caspofungin has been shown in animal studies to have embroyotoxic properties, and therefore has been assigned to class C. It should only be given to pregnant women if the benefit to the mother clearly outweighs the potential risk to her fetus.

Its currently approved therapeutic indications by both organisations include the empirical therapy of presumed fungal infections in febrile, neutropenic adult patients and for salvage therapy in patients treatment of invasive aspergillosis in adult patients whose disease is refractory to, or who are intolerant of, other antifungal agents (i.e., conventional or lipid formulations of amphotericin B and/or itraconazole). Additionally, the FDA approval includes indication for the treatment of candidemia and some specific Candida infections (intra-abdominal abscesses, peritonitis, pleural cavity infections, and esophagitis) and the EMEA approval includes indication for the treatment of general invasive candidiasis in adult patients.

Slowly metabolized by peptide hydrolysis and N-acetylation in liver. Therefore, in case of liver impairment the dose needs to be reduced. Caspofungin also undergoes spontaneous chemical degradation to an open-ring peptide compound, L-747969. Additional metabolism involves hydrolysis into constitutive amino acids and their derivatives, including dihydroxyhomotyrosine and N-acetyl-dihydroxyhomotyrosine.

Caspofungin Market: Overview

This report on the global caspofungin market analyzes the current and future prospects of the market. The report comprises a comprehensive executive summary, including a snapshot that provides overall information of various market segments. The research is a combination of primary and secondary researches. Primary research formed the bulk of the research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2017 to 2027, considering the macro and micro environmental factors. Growth rate for each segment of the global caspofungin market has been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining the market and opportunities has been provided in the overview section. The report also provides insights into the key trends of the caspofungin market. The report includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global caspofungin market.

Market revenue in terms of US$ Mn for the period between 2017 and 2027 along with the compound annual growth rate (CAGR %) from 2019 to 2027 are provided for all the segments, considering 2018 as the base year. The year-on-year growth of the global caspofungin market for each segment is also reflected. Additionally, market-related factors such as favorable reimbursement scenario, expanding distribution channels of caspofungin, and historical year-on-year growth have been taken into consideration while estimating the market size.

Global Caspofungin Market: Key Segments

Based on indication, the global caspofungin market has been segmented into candidiasis and thrush. In terms of distribution channel, the global market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies.

Global Caspofungin Market: Regional Outlook

In terms of region, the global caspofungin market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Additionally, the regions have been divided into major countries/sub-regions. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia & New Zealand, Japan, India, Brazil, GCC Countries, South Africa, Israel, and Mexico.

Companies Mentioned in Report

The report also profiles major players in the global caspofungin market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Teva Pharmaceutical Industries Ltd., Mylan N.V , Merck & Co., Inc., Fresenius SE & Co. KGaA, Gland Pharma Limited, Xellia Pharmaceuticals, and Novartis AG.

The global caspofungin market has been segmented as follows:

Indication

  • Candidiasis
  • Thrush

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Australia & New Zealand
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa

Section 1 Preface 
            1.1 Report Scope and Market Segmentation 
            1.2 Research Highlights

Section 2 Assumptions and Research Methodology 
            2.1 Assumptions
            2.2 Research Methodology

Section 3 Executive Summary
            3.1 Global Caspofungin Market Snapshot
            3.2 Key Industry Developments

Section 4 Market Overview
            4.1 Caspofungin Market Taxonomy
            4.2 Caspofungin Drug Introduction
            4.3 Global Caspofungin Market Size (US$ Mn) Forecast, 2017–2027
            4.4 Global Caspofungin Market: Market Outlook
            4.5 Rise in incidence of invasive candidiasis across the globe
                  4.5.1.Rise in geriatric population
                  4.5.2.Advantages of echinocandins over other antifungal
                  4.5.3.Restraints
                          4.5.3.1 Availability of Generic Drugs
                          4.5.3.2 Emergence of resistant species
                  4.5.4 Opportunities
                          4.5.4.1 Echinocandins, as first line of therapy in candidiasis
                          4.5.4.2 Expansion of Research and Development in Emerging Markets

Section 5 Key Insights
            5.1 Clinical Trial Pipeline Analysis
            5.2 Disease Prevalence & Incidence Rate globally with key countries
            5.3 Supply Chain Analysis
            5.4 Pricing Analysis by Manufacturers

Section 6 Global Caspofungin Market Analysis, by Indication
            6.1 Key Findings
            6.2 Introduction
            6.3 Market Value Share Analysis, by Indication
            6.4 Market Value Forecast, by Indication, 2017–2027
            6.5 Market Analysis, by Indication, 2017–2027
                  6.5.1 Candidiasis
                  6.5.2 Thrush
            6.6 Market Attractiveness, by Indication 

Section 7 Global Caspofungin Market Analysis, by Distribution Channel
            7.1 Key Findings
            7.2 Introduction
            7.3 Market Value Share Analysis, by Distribution Channel
                  7.5.1. Hospital Pharmacies
                  7.5.2 Retail Pharmacies
                  7.5.3 Online Pharmacies
            7.6 Market Attractiveness, by Distribution Channel 

Section 8 Global Caspofungin Market Analysis, by Region
            8.1 Market Value Share Analysis, by Region
            8.2 Market Forecast, by Region
            8.3 Global Caspofungin Market Attractiveness Analysis, by Region

Section 9 North America Caspofungin Market Analysis
            9.1 Market Overview
            9.2 Market Value Share Analysis, by Indication
            9.3 Caspofungin Market Forecast, by Indication
            9.4 Market Value Share Analysis, by Distribution Channel
            9.5 Caspofungin Market Forecast, by Distribution Channel
            9.6 U.S.
                  9.6.1 Canada
            9.7 Market Attractiveness Analysis
                  9.7.1 By Country
                  9.7.2 By Indication
                  9.7.3 By Distribution Channel

Section 10 Europe Caspofungin Market Analysis
            10.1 Market Overview
            10.2 Market Value Share Analysis, by Indication
            10.3 Caspofungin Market Forecast, by Indication
            10.4 Market Value Share Analysis, by Distribution Channel
            10.5 Caspofungin Market Forecast, by Distribution Channel
            10.6 Market Value Share Analysis, by Country/Sub-region
            10.7 Market Forecast, by Country/Sub-region
                  10.7.1 Germany
                  10.7.2 U.K.
                  10.7.3 France
                  10.7.4 Spain
                  10.7.5 Italy
                  10.7.6 Rest of Europe
            10.8 Market Attractiveness Analysis
                  10.8.1 By Country/Sub-region
                  10.8.2 By Indication
                  10.8.3 By Distribution Channel

Section 11 Asia Pacific Caspofungin Market Analysis
            11.1 Market Overview
            11.2 Market Value Share Analysis, by Indication
            11.3 Caspofungin Market Forecast, by Indication
            11.4 Market Value Share Analysis, by Distribution Channel
            11.5 Caspofungin Market Forecast, by Distribution Channel
            11.6 Market Value Share Analysis, by Country/Sub-region
            11.7 Market Forecast, by Country/Sub-region
                  11.7.1 China
                  11.7.2 Japan
                  11.7.3 India
                  11.7.4 Australia & New Zealand
                  11.7.5 Rest of Asia Pacific
            11.8 Market Attractiveness Analysis
                  11.8.1 By Country/Sub-region
                  11.8.2 By Indication
                  11.8.3 By Distribution Channel

Section 12 Latin America Caspofungin Market Analysis
            12.1 Market Overview
            12.2 Market Value Share Analysis, by Indication
            12.3 Caspofungin Market Forecast, by Indication
            12.4 Market Value Share Analysis, by Distribution Channel
            12.5 Caspofungin Market Forecast, by Distribution Channel
            12.6 Market Value Share Analysis, by Country/Sub-region
            12.7 Market Forecast, by Country/Sub-region
                  12.7.1 Brazil
                  12.7.2 Mexico
                  12.7.3 Rest of Latin America
            12.8 Market Attractiveness Analysis
                  12.8.1 By Country/Sub-region
                  12.8.2 By Indication
                  12.8.3 By Distribution Channel

Section 13 Middle East & Africa (MEA) Caspofungin Market Analysis
            13.1 Market Overview
            13.2 Market Value Share Analysis, by Indication
            13.3 Caspofungin Market Forecast, by Indication
            13.4 Market Value Share Analysis, by Distribution Channel
            13.5 Caspofungin Market Forecast, by Distribution Channel
            13.6 Market Value Share Analysis, by Country/Sub-region
            13.7 Market Forecast, by Country/Sub-region
                  13.7.1 GCC Countries
                  13.7.2 South Africa
                  13.7.3 Israel
                  13.7.4 Rest of MEA
            13.8 Market Attractiveness Analysis
                  13.8.1 By Country/Sub-region
                  13.8.2 By Indication
                  13.8.3 By Distribution Channel

Section 14 Company Profiles
            14.1 Market Player - Competition Matrix (By Tier and Size of companies)
            14.2 Market Share Analysis, by Company, 2017
            14.3 Company Profile
                  14.3.1 Teva Pharmaceutical Industries Ltd.
                           14.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
                           14.3.1.2 Financial Overview
                           14.3.1.3 Product Portfolio
                           14.3.1.4 SWOT Analysis
                           14.3.1.5 Strategic Overview
                  14.3.2 Novartis AG
                           14.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
                           14.3.2.2 Financial Overview
                           14.3.2.2 Product Portfolio
                           14.3.2.3 SWOT Analysis
                           14.3.2.4 Strategic Overview
                  14.3.3 Mylan N.V.
                           14.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
                           14.3.3.2 Financial Overview
                           14.3.3.3 Product Portfolio
                           14.3.3.4 SWOT Analysis
                           14.3.3.5 Strategic Overview
                  14.3.4 Merck & Co., Inc. 
                           14.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
                           14.3.4.2 Financial Overview
                           14.3.4.2 Product Portfolio
                           14.3.4.3 SWOT Analysis
                           14.3.4.4 Strategic Overview
                  14.3.5 Fresenius SE & Co. KGaA 
                           14.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
                           14.3.5.2 Financial Overview
                           14.3.5.2 Product Portfolio
                           14.3.5.3 SWOT Analysis
                           14.3.5.4 Strategic Overview
                  14.3.6 Gland Pharma Limited (Shanghai Fosun Pharmaceutical (Group) Co., Ltd.)
                           14.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
                           14.3.6.2 Financial Overview
                           14.3.6.3 Product Portfolio
                           14.3.6.4 SWOT Analysis
                           14.3.6.5 Strategic Overview
                  14.3.7 Xellia Pharmaceuticals 
                           14.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
                           14.3.7.2 Financial Overview
                           14.3.7.3 Product Portfolio
                           14.3.7.4 SWOT Analysis
                           14.3.7.5 Strategic Overview

Table 01: Caspofungin Brands in India and their Prices
Table 02: Caspofungin Brands in Germany and their Prices
Table 03: Pipeline Analysis, by Phase 3 Drugs
Table 04: Country Estimated Burden and Prevalence Rate of Candidiasis 
Table 05: List of Prescription Products
Table 06: List of Prescription Products
Table 07: List of Generic Prescription Products
Table 08: Global Caspofungin Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 09: Global Caspofungin Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 10: Global Caspofungin Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 11: North America Caspofungin Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 12: North America Caspofungin Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 13: North America Caspofungin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 14: Europe Caspofungin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 15: Europe Caspofungin Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 16: Europe Caspofungin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 17: Asia Pacific Caspofungin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 18: Asia Pacific Caspofungin Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 19: Asia Pacific Caspofungin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 20: Latin America Caspofungin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 21: Latin America Caspofungin Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 22: Latin America Caspofungin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 23: Middle East & Africa Caspofungin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 24: Middle East & Africa Caspofungin Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 25: Middle East & Africa Caspofungin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Figure 01: Global Caspofungin Market Snapshot
Figure 02: Global Caspofungin Market Value (US$ Mn) Forecast, 2019–2027
Figure 03: Market Value Share, by Indication, 2018
Figure 04: Market Value Share, by Distribution Channel, 2018
Figure 05: Market Value Share, by Region, 2018
Figure 06: Global Caspofungin Market Value Share Analysis, by Indication, 2018 and 2027
Figure 07: Global Caspofungin Market Revenue (US$ Mn) Forecast, by Candidiasis, 2019–2027 
Figure 08: Global Caspofungin Market Revenue (US$ Mn) Forecast, by Thrush, 2019–2027
Figure 09: Global Caspofungin Market Attractiveness, by Indication, 2019–2027
Figure 10: Global Caspofungin Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 11: Global Caspofungin Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2027
Figure 12: Global Caspofungin Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2027
Figure 13: Global Caspofungin Market Revenue (US$ Mn), by Online Pharmacies, 2017–2027
Figure 14: Global Caspofungin Market Attractiveness, by Distribution Channel, 2019–2027
Figure 15: Global Caspofungin Market Value Share, by Region, 2018 and 2027
Figure 16: Global Caspofungin Market Attractiveness, by Region, 2019–2027
Figure 17: North America Caspofungin Market Value (US$ Mn) Forecast, 2019–2027
Figure 18: North America Caspofungin Market Value Share, by Country, 2018 and 2027
Figure 19: North America Caspofungin Market Attractiveness, by Country, 2019–2027
Figure 20: North America Caspofungin Market Value Share Analysis, by Indication, 2018 and 2027
Figure 21: North America Caspofungin Market Attractiveness, by Indication, 2019–2027
Figure 22: North America Caspofungin Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 23: North America Caspofungin Market Attractiveness, by Distribution Channel, 2019–2027
Figure 24: Europe Caspofungin Market Value (US$ Mn) Forecast, 2019–2027
Figure 25: Europe Caspofungin Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 26: Europe Caspofungin Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 27: Europe Caspofungin Market Value Share Analysis, by Indication, 2018 and 2027
Figure 28: Europe Caspofungin Market Attractiveness, by Indication, 2019–2027
Figure 29: Europe Caspofungin Market Value Share Analysis, by Distribution Channel
Figure 30: Europe Caspofungin Market Attractiveness, by Distribution Channel, 2019–2027
Figure 31: Asia Pacific Caspofungin Market Value (US$ Mn) Forecast, 2019–2027
Figure 32: Asia Pacific Caspofungin Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 33: Asia Pacific Caspofungin Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 34: Asia Pacific Caspofungin Market Value Share Analysis, by Indication, 2018 and 2027
Figure 35: Asia Pacific Caspofungin Market Attractiveness, by Indication, 2019–2027
Figure 36: Asia Pacific Caspofungin Market Value Share Analysis, by Distribution Channel, 2018 and 2027 
Figure 37: Asia Pacific Caspofungin Market Attractiveness, by Distribution Channel, 2019–2027
Figure 38: Latin America Caspofungin Market Value (US$ Mn) Forecast, 2019–2027
Figure 39: Latin America Caspofungin Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 40: Latin America Caspofungin Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 41: Latin America Caspofungin Market Value Share Analysis, by Indication, 2018 and 2027
Figure 42: Latin America Caspofungin Market Attractiveness, by Indication, 2019–2027
Figure 43: Latin America Caspofungin Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 44: Latin America Caspofungin Market Attractiveness, by Distribution Channel, 2019–2027
Figure 45: Middle East & Africa Caspofungin Market Value (US$ Mn) Forecast, 2019–2027
Figure 46: Middle East & Africa Caspofungin Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 47: Middle East & Africa Caspofungin Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 48: Middle East & Africa Caspofungin Market Value Share Analysis, by Indication, 2018 and 2027
Figure 49: Middle East & Africa Caspofungin Market Attractiveness, by Indication, 2019–2027
Figure 50: Middle East & Africa Caspofungin Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 51: Middle East & Africa Caspofungin Market Attractiveness, by Distribution Channel, 2019–2027
Figure 52: Teva Pharmaceutical Industries Ltd., Generic Products Revenue (US$ Mn), 2015–2018
Figure 53: Teva Pharmaceutical Industries Ltd., Generic Products Breakdown of Net Sales (%), by Business Segment, 2018
Figure 54 Teva Pharmaceutical Industries Ltd., R&D Expenses (US$ Mn), 2015–2018
Figure 55: Teva Pharmaceutical Industries Ltd. Breakdown of Generic Products Net Sales (%), by Region, 2018
Figure 56: Sandoz Division Revenue (US$ Mn), 2015–2018
Figure 57: Sandoz Division Breakdown of Net Sales (%), by Region, 2018
Figure 58: Novartis AG, R&D Expenses (US$ Mn), 2015–2018
Figure 59: Novartis AG, Breakdown of Net Sales (%), by Business Segment, 2018
Figure 60: Mylan N.V. Revenue (US$ Mn), 2015–2018
Figure 61: Mylan N.V., Breakdown of Net Sales (%), by Region, 2018
Figure 62: Mylan N.V., R&D Expenses (US$ Mn), 2015-2018
Figure 63: Merck & Co., Inc., Revenue (US$ Mn), 2015–2018
Figure 64: Merck & Co., Inc., Breakdown of Net Sales (%), by Region, 2018
Figure 65: Merck & Co., Inc., R&D Expenses (US$ Mn), 2015–2017
Figure 66: Merck & Co., Inc., Breakdown of Net Sales (%), by Business Segment, 2017
Figure 67: Fresenius Kabi AG, Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 68: Fresenius Kabi AG, Breakdown of Net Sales, by Region, 2018
Figure 69: Fresenius Kabi AG, R&D Expenses (US$ Mn), 2015–2018
Figure 70: Fresenius Kabi AG, Breakdown of Net Sales, by Product Segment, 2018
Figure 71: Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Revenue (US$ Mn), 2015–2017
Figure 72: Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Breakdown of Net Sales (%), by Business Segment, 2018
Figure 73: Shanghai Fosun Pharmaceutical (Group) Co., Ltd., R&D Expenses (US$ Mn), 2015–2017
Figure 74: Xellia Pharmaceuticals Revenue (US$ Mn), 2015–2018
Figure 75: Xellia Pharmaceuticals, Breakdown of Net Sales (%), by Region, 2018
Figure 76: Xellia Pharmaceuticals, R&D Investment (US$ Mn), 2015–2018
Figure 77: Xellia Pharmaceuticals, Breakdown of Net Sales (%), by Business Segment, 2018

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Caspofungin Market